Who are Placebo to Fosfomycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fosfomycin Tromethamine Granules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-fosfomycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Fosfomycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Fosfomycin (Placebo to Fosfomycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic (phosphonic acid derivative). Area: Infectious Disease.

marketed Antibiotic (phosphonic acid derivative) MurA (UDP-N-acetylglucosamine enolpyruvyl transferase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Fosfomycin (Placebo to Fosfomycin) — University Medical Center Goettingen. Fosfomycin is a broad-spectrum antibiotic that inhibits bacterial cell wall synthesis by blocking peptidoglycan cross-linking.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Fosfomycin TARGET	Placebo to Fosfomycin	University Medical Center Goettingen	marketed	Antibiotic (phosphonic acid derivative)	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)
Fosfomycin Tromethamine Granules	Fosfomycin Tromethamine Granules	Benova (Tianjin) Innovative medicine Research Co., Ltd.	phase 3	Antibiotic (phosphonic acid derivative)	MurA (UDP-N-acetylglucosamine enolpyruvyl transferase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic (phosphonic acid derivative) class)

Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
University Medical Center Goettingen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Fosfomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-fosfomycin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab